Previous Article | Next Article 
Journal of Bacteriology, November 1999, p. 7052-7064, Vol. 181, No. 22
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Synergistic Operation of the CAR2
(Ornithine Transaminase) Promoter Elements in Saccharomyces
cerevisiae
Heui-Dong
Park,1
Stephanie
Scott,2
Rajendra
Rai,2
Rosemary
Dorrington,2,
and
Terrance G.
Cooper2,*
Department of Food Science and Technology,
Kyungpook National University, Taegu 702-701, Korea,1 and Department of Microbiology
and Immunology, University of Tennessee, Memphis, Tennessee
381632
Received 7 July 1999/Accepted 7 September 1999
 |
ABSTRACT |
Dal82p binds to the UISALL sites of
allophanate-induced genes of the allantoin-degradative pathway and
functions synergistically with the GATA family Gln3p and Gat1p
transcriptional activators that are responsible for nitrogen catabolite
repression-sensitive gene expression. CAR2, which encodes
the arginine-degradative enzyme ornithine transaminase, is not nitrogen
catabolite repression sensitive, but its expression can be modestly
induced by the allantoin pathway inducer. The dominant activators of
CAR2 transcription have been thought to be the ArgR and
Mcm1 factors, which mediate arginine-dependent induction. These
observations prompted us to investigate the structure of the
CAR2 promoter with the objectives of determining whether
other transcription factors were required for CAR2
expression and, if so, of ascertaining their relative contributions to
CAR2's expression and control. We show that Rap1p binds
upstream of CAR2 and plays a central role in its induced expression irrespective of whether the inducer is arginine or the
allantoin pathway inducer analogue oxalurate (OXLU). Our data also
explain the early report that ornithine transaminase production is
induced when cells are grown with urea. OXLU induction derives from the
Dal82p binding site, which is immediately downstream of the Rap1p site,
and Dal82p functions synergistically with Rap1p. This synergism is
unlike all other known instances of Dal82p synergism, namely, that with
the GATA family transcription activators Gln3p and Gat1p, which occurs
only in the presence of an inducer. The observations reported suggest
that CAR2 gene expression results from strong constitutive
transcriptional activation mediated by Rap1p and Dal82p being balanced
by the down regulation of an equally strong transcriptional repressor,
Ume6p. This balance is then tipped in the direction of expression by
the presence of the inducer. The formal structure of the
CAR2 promoter and its operation closely follow the model
proposed for CAR1.
 |
INTRODUCTION |
All nitrogen catabolite repression
(NCR)-sensitive genes in Saccharomyces cerevisiae have GATA
sequences in their promoters, and their expression is dependent upon
one or both of the GATA family transcriptional activators Gln3p and/or
Gat1p (also called Nil1p) (for a brief review of the GATA factor field,
see the introductions of references 7 and
52). Gln3p has been shown to bind to the GATA
sequences, and both Gln3p and Gat1p have the ability to activate
transcription of a reporter gene in a lexAp-tethering assay
system (7, 52). Expression of the genes encoding components of the arginine- and allantoin-degradative pathways depends upon Gln3p
and Gat1p working synergistically with pathway-specific transcription
factors (47, 61). Arginine and allantoin pathway gene
expression is also subject to induction in response to the presence of
small signal metabolites (8, 9, 23, 37-40, 59, 60). In the
case of the arginine pathway genes (CAR genes), the inducer
is arginine (59) and the transcription factors involved are
ArgRIp, ArgRIIp, ArgRIIIp, and Mcm1p. For the allantoin pathway genes
(DAL and DUR genes), the inducer is allophanate
or its nonmetabolized analogue, oxalurate (OXLU), and the associated
transcription factors are Dal82p and Dal81p (8, 9).
The CAR1 promoter has been extensively studied both
biochemically and genetically (2-4, 11, 12, 14, 18, 23, 25, 59). It consists of up to 14 cis-acting sites, which
bind nine trans-acting factors, Rap1p, Abf1p, Gln3p, Gat1p,
ArgRIp, ArgRIIp, ArgRIIIp, Mcm1p, and Ume6p (3, 10, 13, 19,
27-29, 31, 34-36, 42-44, 47, 51, 58). Proteins that bind to
the Rap1 and Abf1 sites and a GC-rich sequence are necessary to achieve highly induced transcription levels of CAR1 (27-29,
47). The action of these strong, constitutively acting
transcription factors is antagonized by the equally strong negative
action of Ume6p (also called Car80p) bound to the URS1 site
(1, 3, 42, 47-51). The metabolite-responsive promoter
elements are much weaker than those just cited (47) and have
been suggested to tip the balance either toward expression when the
inducer is present and a repressing nitrogen source is absent or toward
quiescence when arginine is absent and/or a repressive nitrogen source
such as glutamine is present (47, 50, 51). Three
cis-acting sites, which are associated with the ArgRI,
ArgRII, ArgRIII, and Mcm1 proteins, mediate arginine-dependent
induction (10, 11, 13, 14, 18, 19, 34-36). NCR-sensitive
CAR1 expression, on the other hand, is mediated by two GATA
sequences associated with Gln3p and Gat1p (47).
Although arginase and ornithine transaminase (encoded by
CAR1 and CAR2) catalyze contiguous enzyme
reactions in the arginine-degradative pathway of S. cerevisiae, production of the two enzymes is regulated somewhat
differently (37-40, 59, 60). While arginine induces production of both arginase and ornithine transaminase, only arginase production is NCR sensitive (14, 37-40, 59, 60). Production of ornithine transaminase, on the other hand, is induced by
allophanate, the last intermediate of the allantoin-degradative
pathway, while CAR1 expression is not (23).
Unlike that of CAR1, the CAR2 promoter has not
been characterized.
The allantoin pathway gene promoters appear to be simpler than those in
the arginine pathway (8, 9). For example, the DAL7 promoter contains three types of sites, each of which
is associated with a different type of regulation. Multiple GATA sequences mediate NCR-sensitive gene expression that depends upon Gln3p
and Gat1p (7-9, 51). DAL7 expression is down
regulated by the action of Dal80p, which antagonizes transcriptional
activation, mediated by Gln3p and Gat1p (9). Finally,
inducer-dependent (allophanate or its nonmetabolized analogue OXLU)
expression depends upon the UISALL site; Dal82p
binds to this site and Dal81p functions in association with it (8,
9, 17). A notable similarity exists in the formal organizations
of the CAR and DAL promoters; the action of
transcriptional activators is antagonized by repressor proteins, and
the balance is shifted by the inducer-responsive transcription factor
(11a, 47).
In all cases studied so far, UISALL and Dal82p
function only in association with the GATA factors Gln3p and Gat1p
(9). Further, genetic data have raised the possibility that
Gln3p and/or Gat1p may interact directly with Dal82p (57). A
UISALL site placed adjacent to a mutated
GATA-containing UASNTR site will suppress its
mutant phenotype. This suppression depends upon the presence of
wild-type Gln3p and Dal82p and correlates with Dal82p binding to
UISALL (57). It does not, however,
depend upon Dal81p or an inducer. Dal81p does not appear to bind to
DAL promoters (4a, 56).
This work has three objectives, namely, to (i) identify the promoter
elements of CAR2 responsible for allophanate-induced expression; (ii) determine whether the overall structure and operation of CAR2 is analogous to those features of CAR1,
i.e., whether CAR2 contains strong, opposing positive and
negative control elements, with the metabolite-responsive elements
shifting the balance; and (iii) determine whether Dal82p can function
in association with global transcription factors other than Gln3p
and/or Gat1p, and if so, which ones. This work does not address
elements and proteins associated with arginine-dependent
transcriptional activation. This aspect of CAR2 gene
regulation has been reported by Messenguy and Dubois and their colleagues.
 |
MATERIALS AND METHODS |
Strains and media.
The S. cerevisiae strain used
for
-galactosidase assays was TCY1 (MAT
lys2
ura3), and the wild-type strain used for electrophoretic mobility
shift assays (EMSAs) was W303-1A (MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 ura3-1). Strains HEY6 and RDY4 are isogenic derivatives of strain TCY1 containing deletions of
the DAL81 and DAL82 genes, respectively. Strain
YLS91 (29) (kindly provided by David Shore) is a derivative
of W303-1A containing two RAP1 genes; one gene is disrupted
by LEU2 (which results in a deletion between the two
BamHI sites at nucleotides 818 and ca. 2200), and the other
has nucleotides 894 to 1584 deleted, which results in a deletion of
amino acids 44 to 303. The RAP1 DNA binding domain is located between
residues 361 and 596 of the 827-amino-acid protein (24).
Therefore, the truncated protein still retains the DNA binding sites
(29). The Escherichia coli strain used for
cloning was HB101 (supE44 hsdS20 recA13 ara-14 proA2 lacY1 galK2
rpsL20 xyl-5 mtl-1). Yeast cultures used for Northern blot
analysis and
-galactosidase assays were grown in medium containing
0.17% yeast nitrogen base without amino acids or ammonium sulfate (YNB
medium) and supplemented with 2% glucose and 0.1% arginine (induced
condition) or 0.1% proline (noninduced condition). OXLU was added to
YNB-proline medium at a final concentration of 61 mg/ml for the
CAR2 induction. The medium used for yeast extract
preparations was YPD (1% yeast extract, 2% Bacto Peptone, 2% dextrose).
Northern blot analysis.
Yeast cultures used for Northern
blot analyses were grown to the mid-log phase (40 to 60 Klett units).
Total RNA was isolated by the method of Carlson and Botstein
(5). Poly(A)+ RNA was isolated with
oligo(dT)-cellulose (Pharmacia Amersham) columns and resolved on 1.4%
agarose-formaldehyde gels (49). The resolved RNAs were
transferred to GeneScreen Plus nylon 66 (Dupont, NEN Research Products)
membranes. The membranes were then hybridized to double-stranded DNA
probes made radioactive by the randomly primed labeling method
(Boehringer Mannheim). The procedures followed for hybridization and
washing were those described in the GeneScreen Plus protocol manual.
PCR.
PCR was carried out with BamHI-digested
plasmid pRS427 containing the CAR2 gene in the
BamHI site of plasmid pBR322 as the template
(48a). PCR primers used in this study were designed to
amplify the CAR2 5' regulatory region shown in each
construct. The PCR mixture consisted of 0.5 µg of template DNA, 100 pmol of each primer, 2.5 U of Taq DNA polymerase, 0.25 mM
concentrations of each deoxynucleoside triphosphate, 10 mM Tris-Cl (pH
8.3), 50 mM KCl, and 2.5 mM MgCl2. The PCR cycle program
for DNA amplification consisted of one cycle of 94°C (5 min) and 30 cycles of 94°C (1 min), 37°C (1 min), and 72°C (3 min) followed
by one cycle of 72°C (5 min). The PCR products were purified with
Sephadex G25 spun columns and subjected to enzyme digestion.
Plasmid constructions.
Plasmid constructions for the
CAR2 5' deletion analysis were carried out by PCR. PCR
products contained CAR2 DNA sequences between various 5'
upstream positions (
634,
530,
470,
420,
380,
350,
302,
251,
233,
205,
177,
165, and
120) and position +3 as well
as SalI and BamHI sites at the 5' and 3' termini of the products, respectively. The fragments were digested with SalI and BamHI and were cloned into
SalI and BamHI sites of plasmid pLG669Z,
described in detail by Guarente et al. (20-22).
Plasmid pHP52, used to assay CAR2 upstream activation
sequence (UAS)-mediated reporter gene expression, is identical to
plasmid pNG15 (27), except that it contains a 2µm yeast
replication origin instead of ARS1, and was constructed as
follows. (i) The 2.2-kb EcoRI DNA fragment, containing a
2µm replication origin, was cloned into plasmid pNG15 which had been
partially digested with EcoRI to delete the TRP1
(also called ARS1)-containing fragment, to yield plasmid
pHP51. (ii) The NcoI restriction site downstream of the
lacZ gene in plasmid pHP51 was destroyed by NcoI
partial digestion and Klenow polymerase reaction to produce plasmid
pHP52. (iii) Synthetic oligonucleotides, containing putative
CAR2 UAS elements, were cloned into the SalI and
EagI sites of the heterologous expression vector pHP52. The
core promoter contained in plasmid pNG15 is a modified fragment (+4 to
1100) from the CYC1 gene. The cloning was done with a
polylinker that replaced the CYC1 sequence from
228 to
700.
Plasmid pHP200 was constructed to assay the effects of mutating one or
more of the
cis-acting elements in the context of a
full-length
CAR2 promoter. PCR primers were designed to
amplify
CAR2 DNA sequences between positions

126 and +3.
SalI and
BamHI
restriction sites (11 bp apart)
were added to the 5' terminus,
and a
BglII site was added to
the 3' terminus. The sequence 5'-CCCTTGCCCTTAGCGGCTGACTGGCT-3'
was changed to 5'-CCCTATAGTCGACCGGCTGGGATCCT-3'. The
PCR product
was digested with
SalI and
BglII and
cloned into plasmid pLG669Z
that had been digested with
SalI
and
BamHI; the
BamHI-
BglII ligation
destroyed the
BamHI site at the junction and fused the
CAR2 sequence
from

126 to +3 in frame to
lacZ.
These steps produced the vector
plasmid pHP200. PCR amplification was
then used to generate DNA
fragments containing wild-type and mutant
alleles of the
CAR2 5' regulatory region between positions

302 and

127. These fragments
were then cloned into plasmid pHP200
digested with
SalI and
BamHI,
reassembling a
full-length
CAR2 promoter fused to
lacZ. The only
substitutions of wild-type sequences were those necessary to introduce
the
SalI restriction site. This site was situated downstream
of
the TATA box to avoid any changes in the putative UAS region of
the
plasmid.

-Galactosidase activities were measured with transformants
which contained the set of plasmids constructed in this way. All
the
DNA fragments derived from synthetic oligonucleotides and
PCR products
were verified in the recombinant plasmids by sequence
analyses
(
53,
54). Other techniques, including DNA manipulation
and
DNA gel electrophoresis, were as described in detail by Sambrook
et al.
(
45).
EMSA.
The sequences of synthetic oligonucleotides used as
DNA probes and competitors are shown in Fig.
1. Cultures of S. cerevisiae W303-1A and YLS91, used for the preparation of crude extracts, were
grown in YPD medium. The protocols for extract preparation and EMSAs
were as described by Luche et al. (31) and Kovari et al.
(29). Within experimental error, the lanes of the gels (depicted as individual autoradiographs) contained the same amounts of
the DNA probes.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Oligonucleotides used as radioactive probes and
competitors in EMSAs. Sequences homologous to Abf1p, Rap1p, and
Dal82p binding sites are indicated with brackets. Mutations in each
site, here and in all other figures, are shown as lowercase letters.
Numbers in the figure indicate the positions of the bases whose
coordinates are given. mt, mutant.
|
|
Yeast and bacterial transformation.
Yeast strains were
transformed with lithium acetate by the method of Ito et al.
(26). E. coli HB101 was transformed by the Tschumper and Carbon modification (55) of the Mandel and
Higa method (33).
-Galactosidase assay.
Assays of
-galactosidase
activities were performed in duplicate and also from duplicate or
triplicate independent yeast transformants by using the procedures and
precautions described in detail earlier (21, 27, 47). Data
from repeated experiments generally varied less than 20%, and data
from duplicate assays varied less than 5%. The patterns of reporter
gene expression observed within each experiment (the results of one
experiment are represented in each figure) were invariant upon
repetition of the experiment, unless otherwise noted. However, as noted
earlier, quantitative comparisons of data are prudent only when all of
the results being compared derive from a single experiment (i.e., data
from within a figure). Enzyme activities are expressed in units defined
by Miller (41) but were based on 10 ml of culture rather
than 1 ml.
 |
RESULTS |
Induced CAR2 expression.
We first established the
CAR2 baseline induction pattern using Northern blot
analysis. Steady-state levels of CAR1 mRNA (our positive
control gene) were much higher in cells provided with arginine as the
nitrogen source than with proline, i.e., CAR1 expression was
highly inducible. (Fig. 2, lanes A and
B). Compared to those of CAR1, CAR2 mRNA levels
are less responsive to arginine largely due to the fact that
substantial basal-level CAR2 expression occurs when proline
is provided as the sole nitrogen source (lanes C and E).
CAR2 expression was induced by OXLU but to a much smaller degree than when arginine was used as the inducer (Fig. 2, lanes C and
D).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 2.
Steady-state levels of CAR1 and
CAR2 mRNAs in S. cerevisiae grown on various
nitrogen sources. Poly(A)+ RNA was prepared from S. cerevisiae 1278b cells grown in YNB media containing proline
(PRO) or arginine (ARG). OXLU, a gratuitous inducer, was added to
YNB-proline medium (PRO+OXLU) at a final concentration of 61 mg/ml for
the CAR2 induction. The same designations for growth
conditions are used throughout this work. Histone H4 mRNA served as a
control for Northern blot loading and transfer efficiencies.
|
|
5' deletion analysis of the CAR2 upstream region.
We began dissection of the CAR2 promoter by constructing a
CAR2-lacZ fusion plasmid (pHP120) (see Materials and
Methods) containing 634 bp of the upstream region. This plasmid
supported two- and eightfold-higher levels of
-galactosidase
production in response to the presence of OXLU and arginine,
respectively (Fig. 3). A series of
deletions removing nucleotides
634 to
302 (plasmids pHP120 to
pHP126) had little effect on
-galactosidase production, suggesting
that this region was not demonstrably required for regulated
CAR2 expression (Fig. 3). Deletion of nucleotides
302 to
251 resulted in three-, four-, and twofold decreases in basal, proline- and OXLU-induced, and arginine-induced levels of
lacZ expression, respectively (Fig. 3, compare plasmids
pHP126 and pHP127). Removal of the next 18 nucleotides to position
233 resulted in further 10-, 11-, and 7-fold decreases in
lacZ expression, respectively (Fig. 3, plasmid pHP128). In
plasmid pHP128, only low levels of arginine-induced reporter gene
expression were observed. Deletion of 28 additional bases to position
205 (plasmid pHP129) resulted in the loss of the remaining
arginine-dependent
-galactosidase production. The same result was
observed with the three subsequent deletions, the last of which
(plasmid pHP132) lacked all sequences 5' of position
120; the TATA
sequence of CAR2 is situated at position
134. These data
demonstrate that the region between CAR2 positions
302 and
233 contains elements that are important for high-level expression
when arginine is used as the nitrogen source as well as for the more
modest level of expression when OXLU is present.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
5' deletion analysis of the CAR2 upstream
region. DNA fragments containing the CAR2 regulatory region
as well as SalI and BamHI restriction sites at
the 5' and 3' termini, respectively, were amplified from
CAR2 DNA by PCR. The PCR products were digested with
SalI and BamHI and cloned into the
SalI and BamHI sites of the lacZ
expression vector pLG669Z (20-22). The set of plasmids was
then used to transform strain TCY1 for analysis. Boxes at the top of
the figure represent sequences that are homologous to various
transcription factor binding sites. T's indicate the positions of TATA
sequences. Numbers at the left of each insert indicate the 5' terminus
of the remaining CAR2 DNA in the CAR2-lacZ fusion
plasmids. Coordinates are indicated relative to the position of the
translation start site in this and all subsequent figures.
|
|
Demonstration of a putative Abf1p binding to the region from
302
to
233 of CAR2.
Inspection of the CAR2 upstream
region from
302 to
233 revealed sequences homologous to ABF1, RAP1,
UISALL and UASARG sites (Fig. 4). Notably absent were
GATAA-containing sequences homologous to UASNTR.
A priori, the presence of sequences homologous to known transcription
factor binding sites is not sufficient reason to conclude that
transcription factors bind to them and mediate CAR2 transcription. Therefore, EMSAs were performed to ascertain whether CAR2 promoter fragments containing these homologous
sequences were indeed able to bind protein. When radioactively labeled
CAR2 fragment HD189 (positions
313 to
271) was incubated
with a wild-type yeast crude cell extract (see Materials and Methods),
two retarded species were observed (Fig.
5, lane B); no retarded species was observed when extract was omitted from the EMSA reaction mixture (lane
A). To assess the binding specificity, we used a mutant allele of
fragment HD189 in which sequences homologous to an ABF1 binding site
were altered in a way previously shown to destroy Abf1p binding
(15, 16, 28). The slower-migrating DNA-protein complex was
lost when the mutant promoter fragment was used as the probe (Fig. 5,
lane C). These data suggested that only this slower-migrating species
was potentially associated with Abf1p binding. The identity of the
protein(s) in the more rapidly migrating complex in lanes B and C
remains unknown.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Protein binding to ARS1 and CAR2
DNA fragments. DNA fragments labeled with 32P at their 5'
ends and containing the HD189 and ARS1 sequences indicated
in Fig. 1 were used as probes. Yeast cell extract (strain W303-1A) was
omitted from the reaction mixture resolved in lanes A and D. All
reaction mixtures contained a 200-fold excess of sheared calf thymus
DNA by sonication as a nonspecific competitor. EXT, minus extract,
W.T., wild type; mut, mutant.
|
|
To determine whether the more slowly migrating species possessed a
migration rate similar to that of a legitimate Abf1p-DNA
complex, we
used a well-characterized, similarly sized DNA fragment
containing the
HMRE ARS1 B domain (
15,
16,
28), which was
used as an EMSA
probe in the analysis of the
CAR1 promoter (
28)
(Fig.
5, lanes D to F). The wild-type HMRE fragment yielded a
retarded
species with a mobility similar to the one observed with
the wild-type
CAR2 fragment (lane E); as expected, retardation
was not
observed with the mutant HMRE fragment (lane
F).
Competition EMSAs further substantiated the specificity of the
DNA-protein complex. In the first of these experiments,
CAR2 fragment HD189 was used as the radioactive probe and its ability
to
form a retarded complex was assayed in the presence of increasing
amounts of nonradioactive HMRE ARS1 B domain DNA as the competitor
(Fig.
6, left panel). The lowest
concentration of competitor DNA
successfully competed with the
CAR2 fragment probe (Fig.
6, left
panel, lanes A to H). In
contrast, when a mutant allele of the
HMRE fragment was used in the
assay, no competition was observed
(Fig.
6, left panel, lanes H to O).
This experiment was then repeated
with the probe and competitor
reversed, i.e., with the HMRE fragment
as the probe and the
CAR2 fragment as the competitor. As shown
in the right panel
of Fig.
6, the
CAR2 fragment was only minimally
able to
compete with the HMRE DNA fragment for protein binding
(lanes A to H).
This is not a surprising result given the dramatic
effectiveness of
HMRE as a competitor in the left panel of the
figure. Together, the
data in Fig.
5 and
6 suggest that a
CAR2 fragment containing
a sequence from positions

313 to

271 binds
to Abf1p. Note that a
more rapidly migrating species in panel
A (for which the
CAR2 DNA probe was used) was equally competed
away by
increasing amounts of wild-type or mutant HMRE DNA, arguing
that this
complex does not depend upon sequences homologous to
Abf1p binding
sites. It is, however, unlikely to be nonspecific
binding of protein to
DNA because the band was not observed when
HMRE DNA was used as the
radioactive probe.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 6.
Competition between CAR2 and ARS1
DNA fragments. An oligonucleotide covering CAR2 positions
313 to 271 (left) or ARS1 positions 748 to 780 and
flanked by SalI and EagI restriction sites
(right) was labeled at its 5' end with 32P and used as the
probe. Competitor DNA was omitted in the reaction mixtures resolved in
lanes G and I. The reaction mixtures in lanes A through F contained
decreasing amounts of the unlabeled ARS1 (left) or
CAR2 (right) oligonucleotide as a competitor (Comp. and
COMP). The reaction mixtures in lanes J through O contained increasing
amounts of the unlabeled ars1 mutant (mut.) (left) or
car2 mutant (right) oligonucleotides; the amounts that were
used are indicated in micrograms ( ). The remaining conditions and
procedures used in the experiment were as described in the legend to
Fig. 5. Strain W303-1A was the source of the crude cell extract
(EXT).
|
|
Demonstration of putative Rap1p binding to the region from
302 to
233 of CAR2.
We next investigated a CAR2
sequence contained in DNA fragment HD190 (CAR2 positions
282 to
247) which was homologous to known Rap1p DNA binding sites
(Fig. 4). One major and one minor retarded species were observed in the
EMSA when extract from the wild-type strain W303-1A was used as the
source of protein (Fig. 7, lane B). When
the assay was repeated with an extract derived from the rap1
mutant strain YLS91 (carrying a truncated, but binding-competent form
of Rap1 [6, 24, 29, 30, 46]), the major retarded species migrated to a new location just below the minor species observed in lane B (Fig. 7, lane C). When a mutant CAR2 DNA
probe (fragment HD192, in which the Rap1p site-homologous sequence is mutated) was used in the assay, little if any of the more slowly migrating DNA-protein complex present in lane B was observed (Fig. 7,
lane D). The more rapidly migrating species in lane B was also observed
in lane D, arguing that it was not associated with the mutated sequence
in fragment HD192. The small amount of DNA-protein complex in lanes C
and D that possessed the same mobility as the major complex observed in
lane B is unlikely to be Rap1p specific because it was also observed in
lane C, which did not contain full-length Rap1p. We compared the data
shown in Fig. 7, lanes A to D, with that obtained with a similarly
sized, well-characterized TEF2 DNA probe previously documented to
contain a Rap1p binding site (6, 24, 29, 30, 46). The
pattern of data obtained in this control experiment (Fig. 7, lanes E to
H) was the same as that observed when the CAR2 fragment was
used (lanes A to D). The EMSA using the TEF2 probe also exhibited the
nonspecific protein-DNA complexes seen in lanes B to D.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 7.
Wild-type and truncated Rap1p binding to CAR2
and TEF2 DNA fragments. DNA fragments 32P
labeled at their 5' ends and containing the HD190 and HD192 sequences
indicated in Fig. 1 were used as probes. Yeast cell extract (EXT) was
omitted from the reaction mixtures resolved in lanes A and E. A
wild-type (strain W303-1A) extract (W.T.) was used in lanes B, D, F,
and H. An extract from a rap1 truncation mutant strain
(mut.) (YLS91) was used in lanes C and G (rap1 ).
|
|
We next assessed the ability of the TEF2 and
CAR2 fragments
to serve as competitors of one another's protein binding. At the
time
this experiment was performed, the Rap1p binding site contained
in the
TEF2 DNA fragment was the strongest one known (
6,
24,
29,
30,
46). As shown in the left panel of Fig.
8, the TEF2
DNA fragment was unable to
serve as an effective competitor of
the
CAR2 fragment for
DNA binding (lanes A to H). In the reverse
situation, i.e., when the
TEF2 fragment was used as the probe
and the
CAR2 fragment
was used as the competitor, strong competition
was observed (Fig.
8,
right panel). In fact, even at the lowest
concentration used, the
wild-type
CAR2 DNA fragment (HD190) effectively
competed
with the TEF2 probe (Fig.
8, right panel, lanes A to
H). However, when
the putative Rap1p binding site contained in
the
CAR2
fragment was mutated, the fragment was no longer able
to serve as the
competitor. As with Abf1p, these data support
the contention that the
CAR2 fragment from positions

282 to

247
contains a
putative Rap1p binding site.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 8.
Competition between CAR2 and TEF2
DNA fragments for protein binding. An oligonucleotide 32P
labeled at its 5' end and covering CAR2 positions 282 to
247 (left) or TEF2 positions 449 to 414 (right) was
used as the probe. The reaction mixtures in lanes A through F contained
decreasing amounts of the unlabeled TEF2 (left) or
CAR2 (right) oligonucleotide as a competitor (Comp. and
COMP). The reaction mixtures in lanes J through O contained increasing
amounts of the unlabeled TEF2 mutant (mut.) (left) or
CAR2 mutant (right) oligonucleotide. The remaining
conditions and procedures used in the experiment were as described in
the legend to Fig. 6. EXT, extract; , microgram amounts.
|
|
Demonstration of putative Dal82p binding to the region from
302
to
233 of CAR2.
The last CAR2 sequence we
investigated was one homologous to UISALL
elements that are situated upstream of allantoin pathway genes (Fig.
4). These elements are Dal82p binding sites that mediate induction of
DAL and DUR gene expression when allophanate or
its analogue, OXLU, is present (9, 17). To determine whether Dal82p bound to the CAR2 UISALL-homologous
sequence (
272 to
211), CAR2 fragment RD43 (Fig. 1) was
incubated with extracts derived from an E. coli culture
transformed with a T-7 expression vector plasmid (pRD4) or one
containing a T-7-DAL82 fusion (plasmid pRD41) (Fig.
9, lanes D to F). No signal was observed
with extract derived from a transformant containing plasmid pRD4 alone
(lane E). In contrast, several DNA-protein complexes were observed with
extract derived from cells containing the plasmid bearing the
T-7-DAL82 fusion (Fig. 9, lane F). Two of these complexes
(indicated by arrows) were specific to the presence of Dal82p. The
Dal82p-specific signal with the fastest mobility has been previously
shown to derive from a Dal82p degradation product (17). The
source of the weak nonspecific signal observed in the lowest-mobility
complex is unknown (Fig. 9, lanes E and F). DAL7 DNA
fragment RD72X, which contains a well-characterized DAL
UISALL element (17), was used in a
control experiment to identify the relative mobility of a bona fide
UISALL-Dal82p complex (Fig. 9, lanes A to C). In
this experiment, the major complexes with the lowest and greatest
mobilities were the only ones that were Dal82p specific and migrated to
positions similar to those observed in lanes D to F.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 9.
Protein binding to CAR2 and DAL7
DNA fragments. DNA fragments labeled with 32P at their 5'
ends and containing the JRD72X and RD43 sequences indicated in Fig. 1
were used as probes. An extract (EXT) from IPTG
(isopropyl- -D-thiogalactopyranoside)-induced E. coli cells harboring plasmid pRD4 (T7) or pRD41
(T-7-DAL82) was prepared as described previously
(17). EMSA reaction conditions were exactly as described in
the work of Dorrington and Cooper (17).
|
|
To further demonstrate that the major complex observed in Fig.
9
derived from a bona fide Dal82p-
CAR2 UISALL
interaction,
we performed a competition EMSA using
CAR2
wild-type (RD43) and
mutant (RD44) fragments as competitors of
DAL7 DNA fragment JRD72X
(Fig.
10). The wild-type fragment was an
effective competitor of
JRD72X DNA binding (lanes A to F). Fragment
RD44, however, which
contained a mutated form of the
CAR2
UISALL, was unable to effectively
compete with
DAL7 for binding to DNA (Fig.
10, lanes H to M). These
data
led to the conclusion that the
CAR2 fragment RD43 contains
a
sequence capable of binding Dal82p.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 10.
Competition between CAR2 and DAL7
DNA fragments. An oligonucleotide labeled at its 5' end with
32P and covering DAL7 positions 241 to 206
(Fig. 1, JRD72X) was used as the probe. The reaction mixtures in lanes
A through E contained decreasing amounts of the unlabeled
CAR2 wild-type oligonucleotide (Fig. 1, RD43), and lanes I
through M contained increasing amounts of the unlabeled CAR2
mutant oligonucleotide (mut) (Fig. 1, RD44). The remaining conditions
and procedures used in the experiment were as described in the legend
to Fig. 6. COMP, competitor; EXT, extract; , microgram quantities.
|
|
Participation of the putative Abf1p, Rap1p, and Dal82p binding
sites in transcription.
The 70-bp CAR2 fragment (
303
to
235), required for high-level CAR2 expression (Fig. 3)
was shown (Fig. 5 to 10) to contain putative Abf1p, Rap1p, and Dal82p
protein binding sites. To determine whether each of these putative
binding sites participated in transcription, we cloned wild-type and
mutant alleles of this fragment into the 2µm-based expression vector
pHP52. As shown in Fig. 11, this
plasmid supported high-level reporter gene expression but exhibited
only a very modest response when OXLU was added to the medium (plasmid pHP152). This modest induction was not surprising because the CAR2 fragment had just been shown to contain putative Abf1
and Rap1 protein binding sites (data in Fig. 5 to 8). If functional Abf1p and Rap1p sites were present, they would participate in activating significant reporter gene expression in the absence of OXLU,
which in turn would result in a relatively poor induction response due
to the high level of basal expression. To test this possibility, we
synthesized a DNA fragment that contained the putative Abf1p and Rap1p
binding sequences, cloned it into the expression vector pHP52 (to yield
plasmid pHP150), and assayed the reporter gene expression it supported.
As anticipated, plasmid pHP150 supported high-level, OXLU-independent
reporter gene expression (Fig. 11). This expression, however, was only
about one-half to one-fourth the level observed when the putative
Dal82p binding site was also present (Fig. 11, compare plasmids pHP152
and pHP150). The slight decrease in activity observed when OXLU was
present is a common observation when OXLU is added to cultures; it is due to toxic effects of OXLU on the cell (8, 9). To assess the contribution of the putative Abf1p binding site contained in
plasmid pHP150, we mutated the putative Abf1p site in the same way as
we had in the EMSA experiments (Fig. 5 and 6). Gene expression supported by the mutant DNA fragment (plasmid pHP163) was about half
that supported by its wild-type counterpart (plasmid pHP150) and only
about 10% of that observed with plasmid pHP152. This result
demonstrates that a mutation that eliminates putative Abf1p binding
(Fig. 5 and 6) also decreases reporter gene transcription here and
supports the idea that these CAR2 sequences comprise a
functional Abf1p binding site.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 11.
-Galactosidase production supported by plasmids
containing synthetic CAR2 DNA fragments. The synthesized DNA
fragments were cloned into the heterologous expression vector pHP52.
Plasmids pHP150 and pHP184 contain native CAR2 sequences,
whereas their derivatives contain mutated sequences in which the
mutations are shown with lowercase letters. The transformation
recipient was strain TCY1.
|
|
We next mutated the putative Rap1p binding site as we did for the
experiments whose results are shown in Fig.
7 and
8 (Fig.
11, plasmid
pHP164); this resulted in a seven- to ninefold decrease
in
lacZ expression compared to that of the wild-type sequence
(plasmid pHP150). With the aforementioned data, reporter gene
expression supported by plasmid pHP150 can be concluded to be
largely
due to the sequences homologous to the Abf1p and Rap1p
sites.
Furthermore, the putative Rap1p binding site appears to
drive greater
reporter gene expression than the putative Abf1p
site.
We next focused on the putative Dal82p binding site situated between
CAR2 positions

254 to

235. As before, we synthesized
an
oligonucleotide containing these positions, cloned it into
an
expression vector, and assayed its ability to support reporter
gene
expression. The plasmid containing this oligonucleotide was
unable to
support

-galactosidase production above the background
level (Fig.
11, plasmids pHP151 and pHP52). This was consistent
with earlier data
showing that the
DAL7 UISALL (Dal82p binding
site) is unable to support transcription in a heterologous expression
vector in the absence of a GATAA-containing
UASNTR site (Gln3p
and/or Gat1p binding site)
(
9).
The observations that plasmid pHP150 supports only one-third of the
lacZ expression of the parent plasmid pHP152 and that
the
remainder of plasmid pHP152 (i.e., plasmid pHP151) supports
none at all
suggest that the putative Dal82p binding site may
function
synergistically with the putative Rap1p site and/or Abf1p
site (Fig.
11). Indeed, the full-length fragment (plasmid pHP152)
supported
significantly greater transcription than the sum of
the levels of
transcription of the isolated fragments (plasmids
pHP150 and pHP151).
To test this suggestion relative to the involvement
of the Rap1p site,
we synthesized an oligonucleotide containing
only the putative Rap1p
and Dal82p binding sites (positions

269
to

235) and analyzed its
ability to support transcription (Fig.
11, plasmid pHP184). This
plasmid supported about two-thirds of
the
lacZ expression
observed with plasmid pHP152 and five- to
six-fold-greater expression
than with plasmid pHP163. To evaluate
the contributions of the
individual sites on plasmid pHP184, we
first mutated the putative Rap1p
site (plasmid pHP185). This mutation
decreased

-galactosidase
production 30- to 40-fold to a level
slightly above background.
Mutation of the putative Dal82p binding
site of plasmid pHP184
decreased the level of reporter gene expression
by about three-fourths.
Moreover, the remaining gene expression
supported by this plasmid was
abolished after addition of OXLU
(Fig.
11, plasmid pHP186); this result
was surprising and was not
reproducible. As expected, mutation of both
the putative Rap1p
and Dal82p binding sites completely destroyed
reporter gene expression
(Fig.
11, plasmid pHP187). These data support
the contention that
Rap1p and Dal82p act synergistically to support
reporter gene
expression.
Finally, we analyzed the phenotypes of the above-described set of
cis-acting mutations in the context of the entire fragment
from

303 to

235 (Fig.
12). Mutation
of the putative Abf1p binding
site (plasmid pHP153) decreased reporter
gene expression by 10
to 20% compared to that of the parent (plasmid
pHP152). In contrast,
mutation of the putative Rap1p binding site
(pHP154) decreased
reporter gene expression 12- to 14-fold. In both
instances, however,
the presence of OXLU resulted in about 20% greater
expression.
Mutation of both the putative Rap1p and Abf1p sites
together eliminated
transcription (plasmid pHP156). These data
corroborate those shown
in Fig.
11.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 12.
-Galactosidase production supported by plasmids
containing synthetic DNA fragments covering the CAR2
regulatory region between positions 303 and 235, which were cloned
into the expression vector pHP52. The transformation recipient and
conditions were as described for Fig. 11.
|
|
The contribution of a putative Dal82p binding site to overall reporter
gene expression supported by plasmid pHP152 appears
unimpressive if it
is evaluated on the basis of an OXLU response.
However, when mutated,
the putative Dal82p binding site of plasmid
pHP152 exhibits a more
dramatic effect. This mutant site supported
only 20 to 40% of the
reporter gene expression supported by plasmid
pHP152 (Fig.
12).
Moreover, addition of OXLU in this case did not
result in an increase
in reporter gene expression but instead
resulted in a small decrease.
These results suggest that there
is a putative Dal82p binding site
participating in
lacZ expression
supported by plasmid
pHP152.
Requirement of Dal82p for OXLU-mediated reporter gene
expression.
OXLU-induced allantoin pathway gene expression
requires participation of the Dal82 and Dal81 proteins (8,
9). Therefore, we determined whether these regulatory proteins
were required for reporter gene expression supported by plasmid pHP152.
-Galactosidase production decreased by up to 75% in the
dal82 deletion mutant relative to that of the wild type
(Fig. 13, plasmid pHP152). Moreover, this decrease was independent of OXLU. However, no decrease in activity
was observed in dal81 deletion mutant cells grown without an
inducer and decreased only 25% when it was present (Fig. 13, plasmid
pHP152). Mutation of the putative Dal82p binding site in plasmid pHP152
resulted in reporter gene expression that was the same as in wild-type,
dal82, and dal81 strains (Fig. 13, plasmid pHP155). Incidentally, this was also the level observed with plasmid pHP152 expressed in the dal82 deletion. We repeated the
above experiments using vectors containing only the putative Rap1p and Dal82p binding sites (Fig. 13, plasmids pHP184 and pHP186). Results similar to those observed with the entire DNA fragment (plasmid pHP152)
were obtained. Again, mutation of the Dal82p binding site or deletion
of the DAL82 gene resulted in three- and fivefold decreases
in
-galactosidase production in proline medium in the presence and
absence of OXLU, respectively. In no case was Dal81p necessary for
basal-level activity, indicating that Dal82p but not Dal81p is
important for reporter gene expression in the absence of OXLU.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 13.
-Galactosidase production in wild-type (TCY1) and
dal82 (RDY4) or dal81 (HEY6) deletion mutant
strains supported by plasmids containing synthetic DNA fragments
covering the CAR2 regulatory regions that were cloned into
the expression vector pHP52. WT, wild type.
|
|
An important test to determine if the three sites described above in
fact function in
CAR2 transcription is to evaluate the
effects of mutations in these sites in the context of a full-length
CAR2 promoter.
CAR2, as mentioned earlier,
contains sequences
homologous to the
URS1 site of
CAR1, the Ume6p (also called Car80p)
repressor binding site
(
1,
49-51). In our analysis of the
CAR1 promoter, we found that the presence of this strong repressor
binding
site masks some of the effects of mutations in the weaker
UAS elements
of that promoter (
47). The contribution of these
weak UASs
could be unmasked by mutating the
URS1 site. Therefore,
we
constructed full-length wild-type and mutant
UAS alleles in
both wild-type and
urs1-minus promoter backgrounds (Fig.
13).
Mutation of the putative Abf1p binding site in the context of a
full-length
CAR2 promoter did not bring about a demonstrable
decrease in

-galactosidase production when the
URS1 site
was
intact (Fig.
14, compare plasmids
pHP201 and pHP203). In a
urs1 mutant background, however,
reporter gene expression decreased
about one-third when cultures were
grown in proline or proline
plus OXLU medium (compare plasmids pHP202
and pHP204). A similar
decrease was not observed under conditions of
high-level arginine-mediated
induction. Mutation of the putative Rap1p
binding site, on the
other hand, produced about a threefold decrease
regardless of
the medium used and whether or not the
URS1
site was mutated (compare
plasmid pHP205 with plasmid pHP206). Mutation
of both the putative
Abf1p and Rap1p sites resulted in about a 50%
decrease relative
to the situation when only the Rap1p site was mutated
under all
conditions tested (Fig.
14, compare pHP205 with pHP211 and
pHP206
with pHP212). The double mutant promoter retained only 10 to
20%
of the wild-type expression levels regardless of the growth
conditions
or the presence of a functional
URS1 element.
This result argues
that even though
CAR2 is induced by
arginine, a large part of
its transcription depends upon constitutively
functioning Rap1p.
A smaller contribution also appears to be made by a
second constitutively
functioning factor, Abf1p.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 14.
Genetic analysis of the putative CAR2 Abf1p
and Rap1p binding sites in the context of a full-length CAR2
promoter. CAR2 DNA fragments between positions 302 and
132 containing wild-type or mutated putative CAR2 Abf1p
and Rap1p binding sites were synthesized chemically or by PCR and
cloned into SalI and BamHI sites of plasmid
pHP200. Reporter gene expression supported by these plasmids was
determined in cells grown in YNB medium containing proline (PRO),
arginine (ARG), or proline plus OXLU (PRO+OXLU). Open and closed boxes
in the inserts represent wild-type and mutated sites, respectively. T,
TATA sequence.
|
|
Finally, we assessed the contribution of the putative Dal82p binding
site to overall
CAR2 expression in a similar manner.
Mutation of this site alone reduced

-galactosidase production
about
30 to 50% when a wild-type
URS1 allele was present (Fig.
15, compare plasmids pHP201 and
pHP207). When the analogous experiment
was carried out with a
urs1 allele,
lacZ expression decreased
25 to 35%
relative to wild-type expression when proline was provided
as the
nitrogen source; no difference was observed with arginine
as the
nitrogen source (Fig.
14, compare plasmid pHP202 with plasmid
pHP208).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 15.
Combinational mutation analysis of the putative
CAR2 Abf1p, Rap1p, and Dal82p binding sites in the context
of a full-length CAR2 promoter. CAR2 DNA
fragments between positions 302 and 132 containing wild-type or
mutated putative CAR2 Abf1p, Rap1p, and Dal82p binding sites
were synthesized chemically or by PCR and cloned into SalI
and BamHI sites of plasmid pHP200. Growth, abbreviations,
and other conditions were as described for Fig. 14.
|
|
We next assayed the effects of mutating the putative Dal82p binding
site with and without the Abf1p and Rap1p sites. The triple
mutant
possessed only 15 to 30% of the wild-type expression levels,
and there
was no effect whatever, beyond its slight toxicity,
when OXLU was added
as the inducer. Further, there was only about
one-fourth of the
wild-type activity when arginine was provided
as the nitrogen source
even though the elements necessary for
arginine-mediated induction were
untouched (Fig.
15, compare plasmid
pHP201 with plasmid pHP213). The
fold induction with arginine,
however, remained the same as in the wild
type, indicating the
continued functioning of the arginine-dependent
transcription
factors (the arginine value divided by the proline
value). These
data demonstrate the level of expression that can be
supported
by the arginine induction system alone. When the experiment
was
repeated with a plasmid in which the
urs1 site was also
mutated,
a slightly smaller fraction of wild-type activity was retained
(6 to 17%) (Fig.
15, compare plasmid pHP202 with plasmid pHP214).
Here, as with plasmid pHP213, there was no OXLU-mediated induction
and
arginine-induced expression reached only 20% of the wild-type
level.
Another way to visualize the contribution of the putative Dal82p
binding site is to compare the level of expression observed
with
mutations in the Abf1p and Rap1p sites with that observed
when all
three sites (Abf1p, Rap1p, and Dal82p) were mutated.
Arginine-induced
reporter gene expression in the Abf1p and Rap1p
site double mutant was
almost twice as great as when the Dal82p
site was also mutated in a
URS1 allele. There was no difference
in the values observed
with the double mutant when proline or
proline plus OXLU was provided
(Fig.
15, compare pHP214 with pHP212
and pHP213 with pHP211). When the
experiment was performed with
a
urs1 allele,

-galactosidase production was up twofold in the
double mutant under
all conditions compared to that of the triple
mutant (Fig.
15, compare
plasmids pHP212 and pHP214). Again, however,
there was no OXLU-induced
expression. The lack of OXLU-induced
expression in these experiments is
not surprising given the necessity
of Rap1p function for the Dal82p
site to mediate transcription.
These data argue that although the
Dal82p site functions synergistically
with the Rap1p site with respect
to OXLU-induced induction, the
Dal82p site also appears to mediate a
twofold enhancement of arginine-induced
expression.
 |
DISCUSSION |
Two criteria must be met to conclude that a promoter contains a
given transcription factor binding site: (i) the transcription factor
must be shown to bind to the putative site and (ii) the putative site
must be shown to be required for or to participate in the gene's
expression. Qualitative EMSAs described in this work fulfilled the
first of these criteria by demonstrating that Rap1p, Abf1p, and Dal82p
bind to sites in the CAR2 upstream region. Based on crude
approximations derived from the competition EMSA data, the Rap1p site
in CAR2 is a reasonably strong one; the CAR2 fragment containing the Rap1p site was an effective competitor of the
TEF2 fragment containing a strong, well-characterized Rap1p site for
protein binding. The Dal82p binding site in CAR2 was also
relatively strong in that its ability to serve as a competitor compared
favorably with that of an analogous site in a DAL7 fragment, one of the better binding sites found among the allantoin pathway genes. In contrast, Abf1p does not bind to the CAR2 fragment
as well as it does to the ARS1 fragment, which contains a
well-characterized Abf1p site. The second criterion was fulfilled
through genetic analysis of CAR2 promoter fragments cloned
into a heterologous expression vector and full-length promoters fused
to lacZ. These results demonstrated that sequences needed
for Rap1p, Abf1p, and Dal82p binding are also required for maximum
levels of CAR2 transcription. Together, the genetic and
biochemical results of this work permit us to conclude that the
CAR2 promoter contains functional Rap1p, Abf1p, and Dal82p
binding sites in addition to the previously identified Ume6p (also
called Car80p) and UASARG sites.
Our results support the conclusion that regulated CAR2
expression depends upon transcriptional activation by constitutively operating global activators (Abf1p and Rap1p) being balanced by a
similarly strong repression being exerted by a global repressor, Ume6p
(also called Car80p) (51). The balance of positive and negative control is then tipped toward expression when an inducer is
present and toward quiescence when it is not. In the case of CAR2, inducers exert their effects through the ArgR proteins
in the presence of arginine and Dal81p and Dal82p when OXLU is
provided. This formal model of transcriptional regulation is identical
to that first proposed for CAR1 (47, 51). It also
explains the early observation that ornithine transaminase production
is increased with urea as the nitrogen source (23); urea is
the precursor of allophanate, the naturally occurring analogue of OXLU
(9).
This work also extends our understanding of the Dal81 and Dal82
proteins. Prior to our experiments, functional
UISALL sites had been found only upstream of the
allantoin pathway genes and were thought to operate exclusively in
conjunction with GATA-containing UASNTR elements
(9, 17, 57, 61). In this work we demonstrate that
UISALL and associated Dal82p can function in
association with elements and factors other than the GATA-containing
UASNTR elements and their associated Gln3p
and/or Gat1p transcriptional activator. This conclusion is supported by
the facts that the CAR2 promoter is devoid of
UASNTR elements and that the role(s) played by
Gln3p and/or Gat1p for the allantoin pathway genes is predominantly
provided by Rap1p in the case of CAR2.
The suggestion that Dal82p mediates CAR2 transcription via
synergistic association with Rap1p influences the interpretation of
earlier experiments concerning Dal82p and Gln3p (57). These experiments showed that placing a functional Dal82p binding site adjacent to a mutant uasNTR site, i.e., one
containing a single mutation in the GATA sequence, suppressed the
mutant phenotype. Suppression required only a properly situated
UISALL element, functional Dal82p, and was not
dependent upon Dal81p or an inducer. At the time these suppression data
were reported, we suggested that Dal82p bound the
UISALL situated adjacent to the mutant
uasNTR site, which facilitated or stabilized
Gln3p binding to the latter site, potentially through a protein-protein
interaction. This scenario remains a viable interpretation of those
earlier results. However, the present data demonstrate that Dal82p can
also function synergistically with a global transcription factor
(Rap1p) having no specific relationship with nitrogen catabolism. Such
a result does not particularly support proposing a direct Gln3p-Dal82p interaction to account for the suppression data. An alternative possibility is that interactions mediating Dal82p-dependent
stabilization of Gln3p binding may occur more indirectly, perhaps
through involvement of components of the SAGA or related core
transcription complexes.
Finally, the present work offers some insight into the biochemical
characteristics of Dal82p operation. The suppression experiments just
discussed are consistent with the idea that
UISALL and Dal82p are able to suppress the GATA
mutations in the absence of an inducer or Dal81p (57). In
correlation with these observations is the repeated demonstration in
this work that Dal82p can enhance transcription in association with
Rap1p or the transcription factors responsible for arginine-mediated
induction, again in the absence of Dal81p or an inducer. In other
words, the participation of Dal81p is not essential for all Dal82p
functions and neither is an inducer. On the other hand, Dal81p is
absolutely required for OXLU-induced gene expression. The separation of
Dal81p and Dal82 functions observed here and earlier will significantly
influence mechanistic studies aimed at understanding the biochemical
functions of these two transcription factors.
 |
ACKNOWLEDGMENTS |
We thank the members of the U.T. Yeast Group who read this
manuscript and offered suggestions for its improvement.
Oligonucleotides used in this study were prepared by the U.T. Molecular
Resource Center.
This work was supported by Public Health Service grant GM-35642 from
the National Institute of General Medical Sciences and the Academic
Research Fund (GE-96-14) of the Ministry of Education, Republic of Korea.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of Tennessee, Memphis, TN
38163. Phone: (901) 448-6175. Fax: (901) 448-8462. E-mail:
tcooper{at}utmem.edu.
Present address: Department of Biochemistry and Microbiology,
Rhodes University, Grahmstown 6140, South Africa.
 |
REFERENCES |
| 1.
|
Anderson, S. F.,
C. M. Steber,
R. E. Esposito, and J. E. Coleman.
1995.
UME6, a negative regulator of meiosis in Saccharomyces cerevisiae, contains a C-terminal Zn2Cys6 binuclear cluster that binds the URS1 DNA sequence in a zinc-dependent manner.
Protein Sci.
4:1832-1843[Medline].
|
| 2.
|
Bechet, J.,
M. Grenson, and J.-M. Wiame.
1970.
Mutations affecting the repressibility of arginine biosynthetic enzymes in Saccharomyces cerevisiae.
Eur. J. Biochem.
12:31-39[Medline].
|
| 3.
|
Bercy, J.,
E. Dubois, and F. Messenguy.
1987.
Regulation of arginine metabolism in Saccharomyces cerevisiae: expression of the three ARGR regulatory genes and cellular localization of their products.
Gene
55:277-285[Medline].
|
| 4.
|
Bossinger, J., and T. G. Cooper.
1977.
Molecular events associated with the induction of arginase in Saccharomyces cerevisiae.
J. Bacteriol.
131:163-173[Abstract/Free Full Text].
|
| 4a.
|
Bricmont, P. A.,
J. R. Daugherty, and T. G. Cooper.
1991.
The DAL81 gene product is required for induced expression of two differently regulated nitrogen catabolic genes in Saccharomyces cerevisiae.
Mol. Cell. Biol.
11:1161-1166[Abstract/Free Full Text].
|
| 5.
|
Carlson, M., and D. Botstein.
1982.
Two differentially regulated mRNAs with different 5' ends encode secreted and intracellular forms of yeast invertase.
Cell
28:145-154[Medline].
|
| 6.
|
Chambers, A.,
C. Stanway,
J. S. H. Tsang,
Y. Henry,
A. J. Kingsman, and S. M. Kingsman.
1990.
ARS binding factor 1 binds adjacent to RAP1 at the UASs of the yeast glycolytic genes PGK and PYK1.
Nucleic Acids Res.
18:5393-5399[Abstract/Free Full Text].
|
| 7.
|
Coffman, J. A.,
R. Rai,
D. M. Loprete,
T. Cunningham,
V. Svetlov, and T. G. Cooper.
1997.
Cross-regulation of four GATA factors that control nitrogen catabolic gene expression in Saccharomyces cerevisiae.
J. Bacteriol.
179:3416-3229[Abstract/Free Full Text].
|
| 8.
|
Cooper, T. G.
1982.
Nitrogen metabolism in Saccharomyces cerevisiae, p. 39-99.
In
J. N. Strathern, E. W. Jones, and J. Broach (ed.), The molecular biology of the yeast Saccharomyces: metabolism and gene expression. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y
|
| 9.
|
Cooper, T. G.
1994.
Allantoin degradative system an integrated transcriptional response to multiple signals, p. 139-169.
In
G. Marzluf, and R. Bambrl (ed.), Mycota III. Springer-Verlag, Berlin, Germany
|
| 10.
|
Crabeel, M.,
M. de Rijcke,
S. Seneca,
H. Heimberg,
I. Pfeiffer, and A. Matisova.
1995.
Further definition of the sequence and position requirements of the arginine control element that mediates repression and induction by arginine in Saccharomyces cerevisiae.
Yeast
11:1367-1380[Medline].
|
| 11.
|
Cunin, R.,
E. Dubois,
G. Vanthienen,
K. Tinel,
A. Jacobs, and M. Crabeel.
1986.
Positive and negative regulation of CAR1 expression in Saccharomyces cerevisiae.
Mol. Gen. Genet.
205:170-175.
|
| 11a.
|
Daugherty, J.,
R. Rai,
T. S. Cunningham, and T. G. Cooper.
1999.
Overlapping positive and negative GATA binding sites mediate inducible DAL7 expression in Saccharomyces cerevisiae.
J. Biol. Chem.
274:28026-28034[Abstract/Free Full Text].
|
| 12.
|
Degols, G.
1987.
Functional analysis of the regulatory region adjacent to the cargB gene of Saccharomyces cerevisiae.
Eur. J. Biochem.
169:193-200[Medline].
|
| 13.
|
DeRijcke, M.,
S. Seneca,
B. Punyammalee,
N. Glansdorf, and M. Crabeel.
1992.
Characterization of the DNA target site for the yeast ARGR regulatory complex: a sequence able to mediate repression or induction by arginine.
Mol. Cell. Biol.
12:68-81[Abstract/Free Full Text].
|
| 14.
|
Deschamps, J.,
E. Dubois, and J.-M. Wiame.
1979.
L-Ornithine transaminase synthesis in Saccharomyces cerevisiae: regulation by inducer exclusion.
Mol. Gen. Genet.
174:225-232[Medline].
|
| 15.
|
Diffley, J. F. X., and B. Stillman.
1988.
Purification of a yeast protein that binds to origins of DNA replication and a transcriptional silencer.
Proc. Natl. Acad. Sci. USA
85:2120-2124[Abstract/Free Full Text].
|
| 16.
|
Diffley, J. F. X., and B. Stillman.
1989.
Similarity between the transcriptional silencer binding proteins ABF1 and RAP1.
Science
246:1034-1038[Abstract/Free Full Text].
|
| 17.
|
Dorrington, R., and T. G. Cooper.
1993.
The DAL82 protein of Saccharomyces cerevisiae binds to the DAL upstream induction sequence (UIS).
Nucleic Acids Res.
21:3777-3784[Abstract/Free Full Text].
|
| 18.
|
Dubois, E.,
J. Bercy, and F. Messenguy.
1987.
Characterization of two genes, ARGRI and ARGRIII, required for specific regulation of arginine metabolism in yeast.
Mol. Gen. Genet.
207:142-148[Medline].
|
| 19.
|
Dubois, E., and F. Messenguy.
1985.
Isolation and characterization of the yeast ARGRII gene involved in regulating both anabolism and catabolism of arginine.
Mol. Gen. Genet.
198:283-289[Medline].
|
| 20.
|
Guarente, L.
1983.
Yeast promoters and lacZ fusion designed to study expression of cloned genes in yeast.
Methods Enzymol.
101:181-191[Medline].
|
| 21.
|
Guarente, L., and T. Mason.
1983.
Heme regulatory transcription of the CYC1 gene of S. cerevisiae via an upstream activation site.
Cell
32:1279-1286[Medline].
|
| 22.
|
Guarente, L., and M. Ptashne.
1981.
Fusion of Escherichia coli lacZ to the cytrochrome c gene of Saccharomyces cerevisiae.
Proc. Natl. Acad. Sci. USA
78:2199-2230[Abstract/Free Full Text].
|
| 23.
|
Hennaut, C.
1981.
Ornithine transaminase synthesis in Saccharomyces cerevisiae: induction by allophanate, intermediate and inducer of the urea degradative pathway adds to arginine induction.
Curr. Genet.
4:69-72.
|
| 24.
|
Henry, Y. A.,
A. Chambers,
J. S. H. Tsang,
A. J. Kingsman, and S. M. Kingsman.
1990.
Characterization of the DNA binding domain of the yeast RAP1 protein.
Nucleic Acids Res.
18:2617-2623[Abstract/Free Full Text].
|
| 25.
|
Hoet, P. R., and J. M. Wiame.
1974.
On the nature of argR mutations in Saccharomyces cerevisiae.
Eur. J. Biochem.
43:87-92[Medline].
|
| 26.
|
Ito, H.,
Y. Fukuda,
K. Murata, and A. Kimura.
1983.
Transformation of intact yeast cells treated with alkali cations.
J. Bacteriol.
153:163-168[Abstract/Free Full Text].
|
| 27.
|
Kovari, L.,
R. Sumrada,
I. Kovari, and T. G. Cooper.
1990.
Multiple positive and negative cis-acting elements mediate induced arginase (CAR1) gene expression in Saccharomyces cerevisiae.
Mol. Cell. Biol.
10:5087-5097[Abstract/Free Full Text].
|
| 28.
|
Kovari, L. Z., and T. G. Cooper.
1991.
Participation of ABF-1 protein in expression of the Saccharomyces cerevisiae CAR1 gene.
J. Bacteriol.
173:6332-6338[Abstract/Free Full Text].
|
| 29.
|
Kovari, L. Z.,
I. Kovari, and T. G. Cooper.
1993.
Participation of RAP1 protein in expression of the Saccharomyces cerevisiae arginase (CAR1) gene.
J. Bacteriol.
175:941-951[Abstract/Free Full Text].
|
| 30.
|
Kurtz, S., and D. Shore.
1991.
RAP1 protein activates and silences transcription of mating-type genes in yeast.
Genes Dev.
5:616-628[Abstract/Free Full Text].
|
| 31.
|
Luche, R. M.,
R. Sumrada, and T. G. Cooper.
1990.
A cis-acting element present in multiple genes serves as a repressor-protein binding site for the yeast CAR1 gene.
Mol. Cell. Biol.
10:3884-3995[Abstract/Free Full Text].
|
| 32.
|
Lustig, A. J.,
S. Kurtz, and D. Shore.
1990.
Involvement of the silencer and UAS binding protein RAP1 in regulation of telomere length.
Science
250:549-553[Abstract/Free Full Text].
|
| 33.
|
Mandel, M., and A. Higa.
1970.
Calcium-dependent bacteriophage DNA infection.
J. Mol. Biol.
53:159-162[Medline].
|
| 34.
|
Messenguy, F., and E. Dubois.
1993.
Genetic evidence for a role for MCM1 in the regulation of arginine metabolism in Saccharomyces cerevisiae.
Mol. Cell. Biol.
13:2586-2592[Abstract/Free Full Text].
|
| 35.
|
Messenguy, F.,
E. Dubois, and C. Boonchird.
1991.
Determination of the DNA-binding sequences of ARGR proteins to arginine anabolic and catabolic promoters.
Mol. Cell. Biol.
11:2852-2863[Abstract/Free Full Text].
|
| 36.
|
Messenguy, F.,
E. Dubois, and F. Descamps.
1986.
Nucleotide sequence of the ARGRII regulatory gene and amino acid sequence homologies between ARGRII, PPRI and GAL4 regulatory proteins.
Eur. J. Biochem.
57:77-81.
|
| 37.
|
Middlehoven, W. J.
1964.
The pathway of arginine breakdown in Saccharomyces cerevisiae.
Biochim. Biophys. Acta
93:650-652[Medline].
|
| 38.
|
Middlehoven, W. J.
1968.
The derepression of arginase and ornithine transaminase in nitrogen-starved baker's yeast.
Biochim. Biophys. Acta
156:440-443[Medline].
|
| 39.
|
Middlehoven, W. J.
1969.
Enzyme repression in the arginine pathway of Saccharomyces cerevisiae.
Antonie Leeuwenhoek J. Microbiol. Serol.
35:215-226.
|
| 40.
|
Middlehoven, W. J.
1970.
Induction and repression of arginase and ornithine transaminase in baker's yeast.
Antonie Leeuwenhoek J. Microbiol. Serol.
36:1-19.
|
| 41.
|
Miller, J. H.
1972.
Experiments in molecular genetics.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y
|
| 42.
|
Park, H.-D.,
R. M. Luche, and T. G. Cooper.
1992.
The yeast UME6 gene product is required for transcriptional repression mediated by the CAR1 URS1 repressor binding site.
Nucleic Acids Res.
20:1909-1915[Abstract/Free Full Text].
|
| 43.
|
Qui, H. F.,
E. Dubois,
P. Broen, and F. Messenguy.
1990.
Functional analysis of ARGRI and ARGRIII regulatory proteins involved in the regulation of arginine metabolism in Saccharomyces cerevisiae.
Mol. Gen. Genet.
222:192-200[Medline].
|
| 44.
|
Rai, R.,
J. R. Daugherty, and T. G. Cooper.
1995.
UASNTR functioning in combination with other UAS elements underlies exceptional patterns of nitrogen regulation in Saccharomyces cerevisiae.
Yeast
11:247-260[Medline].
|
| 45.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y
|
| 46.
|
Shore, D., and K. Nasmyth.
1987.
Purification and cloning of a DNA binding protein from yeast that binds to both silencer and activator elements.
Cell
51:721-732[Medline].
|
| 47.
|
Smart, W. C.,
J. A. Coffman, and T. G. Cooper.
1996.
Combinatorial regulation of the Saccharomyces cerevisiae CAR1 (arginase) gene promoter in response to multiple environmental signals.
Mol. Cell. Biol.
16:5876-5887[Abstract].
|
| 48.
|
Strich, R.,
R. T. Surosky,
C. Steber,
E. Dubois,
F. Messenguy, and R. E. Esposito.
1994.
UME6 is a key regulator of nitrogen repression and meiotic development.
Genes Dev.
8:796-810[Abstract/Free Full Text].
|
| 48a.
| Sumrada, R. Personal communication.
|
| 49.
|
Sumrada, R., and T. G. Cooper.
1982.
Isolation of the CAR1 gene from Saccharomyces cerevisiae and analysis of its expression.
Mol. Cell. Biol.
2:1514-1523[Abstract/Free Full Text].
|
| 50.
|
Sumrada, R. A., and T. G. Cooper.
1985.
Point mutation generates constitutive expression of an inducible eukaryotic gene.
Proc. Natl. Acad. Sci. USA
82:643-647[Abstract/Free Full Text].
|
| 51.
|
Sumrada, R. A., and T. G. Cooper.
1987.
Ubiquitous expression sequences control activation of inducible arginase gene in yeast.
Proc. Natl. Acad. Sci. USA
84:3997-4001[Abstract/Free Full Text].
|
| 52.
|
Svetlov, V., and T. G. Cooper.
1997.
The minimal transactivation region of Saccharomyces cerevisiae Gln3p is localized to 13 amino acids.
J. Bacteriol.
179:7644-7652[Abstract/Free Full Text].
|
| 53.
|
Tabor, S., and C. C. Richardson.
1987.
DNA sequence analysis with a modified bacteriophage T7 DNA polymerase.
Proc. Natl. Acad. Sci. USA
84:4767-4771[Abstract/Free Full Text].
|
| 54.
|
Taylor, G.,
M. McPherson, and D. Hames.
1994.
PCRII: a practical approach.
IRL Press, New York, N.Y
|
| 55.
|
Tschumper, G., and J. Carbon.
1980.
Sequence of a yeast DNA fragment containing a chromosomal replicator and the TRP1 gene.
Gene
10:1157-1166.
|
| 56.
|
Turoscy, V., and T. G. Cooper.
1982.
Pleiotropic control of five eucaryotic genes by multiple regulatory elements.
J. Bacteriol.
151:1237-1246[Abstract/Free Full Text].
|
| 57.
|
van Vuuren, H. J. J.,
J. R. Daugherty,
R. Rai, and T. G. Cooper.
1991.
Upstream induction sequence, the cis-acting element required for response to the allantoin pathway inducer and enhancement of operation of the nitrogen-regulated upstream activation sequence in Saccharomyces cerevisiae.
J. Bacteriol.
173:7186-7195[Abstract/Free Full Text].
|
| 58.
|
Viljoen, M.,
L. Z. Kovari,
I. A. Kovari,
H.-D. Park,
H. J. J. van Vuuren, and T. G. Cooper.
1992.
Tripartite structure of the Saccharomyces cerevisiae arginase (CAR1) gene inducer-responsive upstream activation sequence.
J. Bacteriol.
174:6831-6839[Abstract/Free Full Text].
|
| 59.
|
Whitney, P. A., and B. Magasanik.
1973.
The induction of arginase in Saccharomyces cerevisiae.
J. Biol. Chem.
248:6197-6202[Abstract/Free Full Text].
|
| 60.
|
Wiame, J.-M.
1971.
The regulation of arginine metabolism in Saccharomyces cerevisiae: exclusion mechanism.
Curr. Top. Cell. Regul.
4:1-38.
|
| 61.
|
Yoo, H.-S., and T. G. Cooper.
1989.
The DAL7 promoter consists of multiple elements that cooperatively mediate regulation of the gene's expression.
Mol. Cell. Biol.
9:3231-3243[Abstract/Free Full Text].
|
Journal of Bacteriology, November 1999, p. 7052-7064, Vol. 181, No. 22
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Xiao, Y., Mitchell, A. P.
(2000). Shared Roles of Yeast Glycogen Synthase Kinase 3 Family Members in Nitrogen-Responsive Phosphorylation of Meiotic Regulator Ume6p. Mol. Cell. Biol.
20: 5447-5453
[Abstract]
[Full Text]
-
Messenguy, F., Vierendeels, F., Scherens, B., Dubois, E.
(2000). In Saccharomyces cerevisiae, Expression of Arginine Catabolic Genes CAR1 and CAR2 in Response to Exogenous Nitrogen Availability Is Mediated by the Ume6 (CargRI)-Sin3 (CargRII)-Rpd3 (CargRIII) Complex. J. Bacteriol.
182: 3158-3164
[Abstract]
[Full Text]
-
Scott, S., Dorrington, R., Svetlov, V., Beeser, A. E., Distler, M., Cooper, T. G.
(2000). Functional Domain Mapping and Subcellular Distribution of Dal82p in Saccharomyces cerevisiae. J. Biol. Chem.
275: 7198-7204
[Abstract]
[Full Text]
-
Scott, S., Abul-Hamd, A. T., Cooper, T. G.
(2000). Roles of the Dal82p Domains in Allophanate/Oxalurate-dependent Gene Expression in Saccharomyces cerevisiae. J. Biol. Chem.
275: 30886-30893
[Abstract]
[Full Text]